<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Rayman, N.</title>
    <link>http://repub.eur.nl/res/aut/12339/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>The Expression and Prognostic Value of the Peripheral Cannabinoid Receptor in Hermatological Malignancies (Doctoral Thesis)</title>
      <link>http://repub.eur.nl/res/pub/32090/</link>
      <pubDate>2011-09-23T00:00:00Z</pubDate>
      <description>Non-Hodgkin’s lymphoma’s (NHLs) are a heterogeneous group of hematological
malignancies with a large variation in clinical presentation, morphological appearance
and prognosis. The NHLs make up the largest group (40-50%) of all hematological
malignancies. In 2007, 17.700 people in the Netherlands had a non-Hodgkin’s lymphoma.
Of these cases, 1.2/1000 was male and 1.2/1000 was female. The number of newly
diagnosed NHL was 2800. In the same year, 1061 succumbed to the disease (585 male,
476 female)1.
NHLs almost always arise from cells of the immune system resulting, in either
B-cell or T-cell lymphomas. Most (approximately 85%) NHLs arise from their normal
B-cell counterparts whereas a minority (approximately 15%) is derived from T-cells. Of
the NHLs, approximately 65% arise in lymph nodes (nodal type), whereas the remaining
35% can arise in any organ (extra-nodal type). The most recent WHO classifi cation
contains about 50 different (clinico-pathological) entities. Each entity is considered to
have a normal physiological counterpart refl ecting the various differentiation stages in the
lymphoid organs or bone marrow.</description>
    </item> <item>
      <title>The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner (Article)</title>
      <link>http://repub.eur.nl/res/pub/8184/</link>
      <pubDate>2004-01-01T00:00:00Z</pubDate>
      <description>Cb2, the gene encoding the peripheral cannabinoid receptor, is located in
      a common virus integration site and is overex-pressed in retrovirally
      induced murine myeloid leukemias. Here we show that this G protein-coupled
      receptor (GPCR) is also aberrantly expressed in a high percentage of human
      acute myeloid leukemias. We investigated the mechanism of transformation
      by Cb2 and demonstrate that aberrant expression of this receptor on
      hematopoietic precursor cells results in distinct effects depending on the
      ligand used. Cb2-expressing myeloid precursors migrate upon stimulation by
      the endocannabinoid 2-arachidonoylglycerol and are blocked in neutrophilic
      differentiation upon exposure to another ligand, CP55940. Both effects
      depend on the activation of G(alphai) proteins and require the
      mitogen-induced extracellular kinase/extracellular signal-regulated kinase
      (MEK/ERK) pathway. Down-regulation of cyclic adenosine monophosphate
      (cAMP) levels upon G(alphai) activation is important for migration
      induction but is irrelevant for the maturation arrest. Moreover, the
      highly conserved G protein-interacting DRY motif, present in the second
      intracellular loop of GPCRs, is critical for migration but unimportant for
      the differentiation block. This suggests that the Cb2-mediated
      differentiation block requires interaction of G(alphai) proteins with
      other currently unknown motifs. This indicates a unique mechanism by which
      a transforming GPCR, in a ligand-dependent manner, causes 2 distinct
      oncogenic effects: altered migration and block of neutrophilic
      development.</description>
    </item>
  </channel>
</rss>